Lantheus Holdings Inc (LNTH) - Total Assets
Based on the latest financial reports, Lantheus Holdings Inc (LNTH) holds total assets worth $2.23 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Lantheus Holdings Inc to assess how comfortably operating cash covers total debt obligations.
Lantheus Holdings Inc - Total Assets Trend (2012–2025)
This chart illustrates how Lantheus Holdings Inc's total assets have evolved over time, based on quarterly financial data. See LNTH net assets for net asset value and shareholders' equity analysis.
Lantheus Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Lantheus Holdings Inc's total assets of $2.23 Billion consist of 40.4% current assets and 59.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.1% |
| Accounts Receivable | $358.64 Million | 16.1% |
| Inventory | $64.67 Million | 2.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $722.78 Million | 32.5% |
| Goodwill | $239.52 Million | 10.8% |
Asset Composition Trend (2012–2025)
This chart illustrates how Lantheus Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Lantheus Holdings Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lantheus Holdings Inc's current assets represent 40.4% of total assets in 2025, an increase from 29.7% in 2012.
- Cash Position: Cash and equivalents constituted 16.1% of total assets in 2025, up from 10.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 25.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 32.5% of total assets.
Lantheus Holdings Inc Competitors by Total Assets
Key competitors of Lantheus Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Livzon Pharmaceutical Group Inc
SHE:000513
|
China | CN¥24.19 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Canopy Growth Corp
TO:WEED
|
Canada | CA$1.11 Billion |
|
LAVIPHARM S.A. NA EO 1
F:BXA0
|
Germany | €125.48 Million |
Lantheus Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.70 | 5.52 | 2.61 |
| Quick Ratio | 2.51 | 5.23 | 2.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $566.54 Million | $1.09 Billion | $103.76 Million |
Lantheus Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Lantheus Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.42 |
| Latest Market Cap to Assets Ratio | 2.21 |
| Asset Growth Rate (YoY) | 12.5% |
| Total Assets | $2.23 Billion |
| Market Capitalization | $4.93 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Lantheus Holdings Inc's assets at a significant premium (2.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Lantheus Holdings Inc's assets grew by 12.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lantheus Holdings Inc (2012–2025)
The table below shows the annual total assets of Lantheus Holdings Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.23 Billion | +12.48% |
| 2024-12-31 | $1.98 Billion | +19.94% |
| 2023-12-31 | $1.65 Billion | +24.97% |
| 2022-12-31 | $1.32 Billion | +52.96% |
| 2021-12-31 | $863.78 Million | -0.69% |
| 2020-12-31 | $869.82 Million | +114.28% |
| 2019-12-31 | $405.92 Million | -7.71% |
| 2018-12-31 | $439.83 Million | +14.58% |
| 2017-12-31 | $383.86 Million | +50.00% |
| 2016-12-31 | $255.90 Million | +5.58% |
| 2015-12-31 | $242.38 Million | -2.88% |
| 2014-12-31 | $249.57 Million | -4.49% |
| 2013-12-31 | $261.31 Million | -19.51% |
| 2012-12-31 | $324.65 Million | -- |
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceut… Read more